Product Information

MAVYRET 100-40 MG TABLET is a brand product labeled by AbbVie Inc., priced at $153.0541 per EA under NDC 00074262528. Its NADAC has been published 368 times since Jul 18, 2018.

MAVYRET 100-40 MG TABLET

Glecaprevir and Pibrentasvir
$153.0541per EA

Strength

100; 40 mg/1; mg/1

Manufacturer

AbbVie Inc.

NDC

00074262528

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

6/17/2026

Active Ingredients

GLECAPREVIR; PIBRENTASVIR

Approval Type

New Drug (NDA)

FDA Application

NDA209394

On Market Since

8/3/2017

Pharmacological Classes

Breast Cancer Resistance Protein Inhibitors
Breast Cancer Resistance Protein Inhibitors
Cytochrome P450 1A2 Inhibitors
Cytochrome P450 1A2 Inhibitors
Cytochrome P450 3A Inhibitors
Cytochrome P450 3A Inhibitors
HCV NS3/4A Protease Inhibitors
Hepatitis C Virus NS3/4A Protease Inhibitor
Hepatitis C Virus NS5A Inhibitor
Organic Anion Transporting Polypeptide 1B1 Inhibitors
Organic Anion Transporting Polypeptide 1B1 Inhibitors
Organic Anion Transporting Polypeptide 1B3 Inhibitors
Organic Anion Transporting Polypeptide 1B3 Inhibitors
P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors
UGT1A1 Inhibitors
UGT1A1 Inhibitors

Price Statistics

The NADAC for MAVYRET 100-40 MG TABLET has been published 368 times since Jul 18, 2018, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$153.0541 per EA
All-time high$153.3945 (Sep 16, 2020)
All-time low$152.4200 (Jul 17, 2024)
52-week high$153.0769
52-week low$152.7714
Median price$152.9488
Average price$152.9555
Largest weekly change+0.3% (Feb 19, 2020)
Weeks tracked368
Tracking sinceJul 18, 2018

Price History

1W

0.0%

1M

-0.0%

3M

+0.1%

6M

+0.1%

1Y

+0.2%

3Y

+0.2%

5Y

-0.0%

All

-0.2%

Generic Alternatives

The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of MAVYRET 100-40 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for MAVYRET 100-40 MG TABLET, manufactured by AbbVie Inc., is $153.0541 per EA (NDC 00074262528), effective Jun 24, 2026.

How has the price of MAVYRET 100-40 MG TABLET changed over time?

Over the history we have for it, the NADAC for MAVYRET 100-40 MG TABLET has held within roughly two percent of its current level. It has been tracked across 368 weekly CMS publications since Jul 18, 2018.

What are the highest and lowest recorded NADAC prices for MAVYRET 100-40 MG TABLET?

Since Jul 18, 2018, the NADAC for MAVYRET 100-40 MG TABLET has ranged from a low of $152.4200 (Jul 17, 2024) to a high of $153.3945 (Sep 16, 2020), with a median of $152.9488 per EA.

Are there cheaper alternatives to MAVYRET 100-40 MG TABLET?

1 NADAC-published product shares the same active ingredient, strength, and dosage form as MAVYRET 100-40 MG TABLET, but none are currently priced below it.

Who manufactures MAVYRET 100-40 MG TABLET?

MAVYRET 100-40 MG TABLET (NDC 00074262528) is labeled by AbbVie Inc., and CMS classifies it as a brand product.